COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN

Turner D1, Huang Y2, Martín-de-Carpi J3, Aloi M4, Focht G1, Kang B5, Zhou Y2, Sanchez C6, Kappelman MD7, Uhlig HH8, Pujol-Muncunill G3, Ledder O1, Lionetti P9, Dias JA10, Ruemmele FM11, Russell RK12; Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2020 Mar 31. doi: 10.1097/MPG.0000000000002729. [Epub ahead of print]


Author information

1 Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel.

2 Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

3 Hospital Sant Joan de Déu, Barcelona, Spain.

4 Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Italy.

5 Kyungpook National University Children's Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

6 Pediatric Gastrointestinal Unit H.G.U. Gregorio Maranon, Madrid, Spain.

7 Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

8 Translational Gastroenterology Unit, University of Oxford, Department of Paediatrics, John Radcliffe Hospital, University of Oxford, Biomedical Research Center Oxford, UK.

9 Departement NEUROFARBA- University of Florence - Meyer children's Hospital- Florence, Italy.

10 Pediatric Gastroenterology, Centro Hospitalar Universitário S. João, Porto, Portugal.

11 Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, France.

12 Department of Paediatric Gastroenterology, The Royal Hospital for Sick Children, Edinburgh.


INTRODUCTION: With the current COVID-19 pandemic, concerns have been raised about the risk to children with inflammatory bowel diseases (IBD). We aimed to collate global experience and provide provisional guidance for managing paediatric IBD (PIBD) in the era of COVID-19.

METHODS: An electronic reporting system of children with IBD infected with SARS-CoV-2 has been circulated among 102 PIBD centres affiliated with the Porto and Interest-group of ESPGHAN. A survey has been completed by major PIBD centres in China and South-Korea to explore management during the pandemic. A third survey collected current practice of PIBD treatment. Finally guidance points for practice have been formulated and voted upon by 37 PIBD authors and Porto group members.

RESULTS: Eight PIBD children had COVID-19 globally, all with mild infection without needing hospitalization despite treatment with immunomodulators and/or biologics. No cases have been reported in China and South Korea but biologic treatment has been delayed in 79 children, of whom 17 (22%) had exacerbation of their IBD. Among the Porto group members, face-to-face appointments were often replaced by remote consultations but almost all did not change current IBD treatment. Ten guidance points for clinicians caring for PIBD patients in epidemic areas have been endorsed with consensus rate of 92-100%.

CONCLUSIONS: Preliminary data for PIBD patients during COVID-19 outbreak are reassuring. Standard IBD treatments including biologics should continue at present through the pandemic, especially in children who generally have more severe IBD course on one hand, and milder SARS-CoV-2 infection on the other.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.